Clinical Trials

28 enrolled

Phase 1 Not yet recruiting

Melanoma, Neoplasm Metastasis, Recurrence

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

15 enrolled

Uveal Melanoma

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

36 enrolled

Phase 1 Active not recruiting

Melanoma

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

67 enrolled

Phase 1 Active not recruiting

Uveal Melanoma

NCT03816332 2025-10-09

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

12 enrolled 13 charts

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05004025 2025-08-15

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

10 enrolled

Phase 1 Active not recruiting

Uveal Melanoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Phase 1 Recruiting

12 enrolled

Melanoma, Skin Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

221 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01703507 2025-05-16

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03922880 2025-05-15

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

9 enrolled

Uveal Melanoma

NCT04463368 2025-03-28

SCANDIUM II

18 enrolled

Uveal Melanoma

NCT05909995 2025-02-18

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

DermatologicGastrointestinalGenitourinary

8 enrolled

Turcot syndrome, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT04121676 2025-01-13

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

91 enrolled

Melanoma

NCT04967196 2024-12-10

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

6 enrolled

Melanoma

NCT05169957 2024-11-05

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

2 enrolled

Uveal Melanoma, Melanoma

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

11 enrolled

Melanoma

NCT03752398 2024-07-05

DUET-3

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

198 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01621490 2024-04-23

PD-1

170 enrolled 34 charts

Melanoma

NCT03798639 2024-04-12

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

7 enrolled

Carcinoma, Merkel Cell

NCT01738139 2024-03-21

Ipilimumab and Imatinib Mesylate in Advanced Cancer

DermatologicGastrointestinalSarcoma

68 enrolled

Melanoma, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

22 enrolled 14 charts

Melanoma

NCT03068624 2024-01-25

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 1 Unknown

34 enrolled

Uveal Melanoma

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

3 enrolled 5 charts

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

73 enrolled

Melanoma

NCT00790010 2023-05-11

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

46 enrolled

Melanoma

NCT03408587 2023-05-06

CLEVER

11 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Uveal Melanoma, Coxsackievirus Infections, Virus Diseases

NCT04311710 2023-02-24

CheckMate 76U

DermatologicGastrointestinalGenitourinaryThoracic

21 enrolled

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

17 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT02307149 2023-01-17

MITCI

50 enrolled

Melanoma

NCT02659540 2022-10-28

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

20 enrolled 15 charts

Melanoma

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

8 enrolled 16 charts

Melanoma, Neoplasms

NCT01838200 2022-10-12

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

5 enrolled 12 charts

Melanoma

NCT02437279 2022-04-15

OpACIN

Phase 1 Unknown

20 enrolled

Melanoma

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

15 enrolled

Melanoma

NCT02381314 2022-02-08

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

24 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03425461 2021-04-02

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

6 enrolled

Melanoma

NCT01024231 2021-03-22

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

127 enrolled 28 charts

Melanoma

NCT03597282 2020-09-03

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

22 enrolled

Melanoma

NCT03565406 2020-05-21

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

11 enrolled

Melanoma

NCT02516527 2020-05-01

A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

25 enrolled

Melanoma

NCT04274816 2020-02-18

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

13 enrolled

Melanoma

NCT02117362 2019-03-21

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

8 enrolled

Melanoma

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

BreastDermatologicHead & NeckLymphoid

80 enrolled

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer